Literature DB >> 2184878

Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU Group.

D Newling1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2184878      PMCID： PMC1971356          DOI： 10.1038/bjc.1990.112

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  14 in total

1.  Benign papilloma or papillary carcinoma of the bladder?

Authors:  L F Greene; K A Hanash; G M Farrow
Journal:  J Urol       Date:  1973-08       Impact factor: 7.450

2.  The management of superficial bladder tumours with intravesical Epodyl.

Authors:  P R Riddle
Journal:  Br J Urol       Date:  1973-02

3.  Papilloma of the urinary bladder.

Authors:  R I Lerman; R V Hutter; W F Whitmore
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

4.  Mitomycin C bladder instillation therapy for bladder tumors.

Authors:  T Mishina; K Oda; S Murata; H Ooe; Y Mori
Journal:  J Urol       Date:  1975-08       Impact factor: 7.450

5.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

6.  Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma.

Authors:  K G Burnand; P J Boyd; M E Mayo; K E Shuttleworth; R W Lloyd-Davies
Journal:  Br J Urol       Date:  1976-02

7.  Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.

Authors:  S A Brosman
Journal:  J Urol       Date:  1982-07       Impact factor: 7.450

8.  Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group.

Authors:  O Dalesio; C C Schulman; R Sylvester; M De Pauw; M Robinson; L Denis; P Smith; G Viggiano
Journal:  J Urol       Date:  1983-04       Impact factor: 7.450

9.  Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

Authors:  D L Lamm; D E Thor; S C Harris; J A Reyna; V D Stogdill; H M Radwin
Journal:  J Urol       Date:  1980-07       Impact factor: 7.450

10.  Mitomycin C in superficial bladder cancer: 24-month follow-up.

Authors:  J J Somerville; D W Newling; B Richards; M R Robinson; P H Smith
Journal:  Br J Urol       Date:  1985-12
View more
  9 in total

1.  Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?

Authors:  J S Teppema; E C de Boer; P A Steerenberg; A P van der Meijden
Journal:  Urol Res       Date:  1992

2.  Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder.

Authors:  J Zorzos; D V Skarlos; P Pozatzidou; A Zizi; A Bakiras; S Koritsiadis; D Pectasidis; P Koutsioumba; A A Epenetos; M Likourinas
Journal:  Urol Res       Date:  1994

Review 3.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy.

Authors:  R R Hall; M K Parmar; A B Richards; P H Smith
Journal:  BMJ       Date:  1994-01-22

Review 5.  BCG in the treatment of superficial cancer of the bladder: a review.

Authors:  S Friberg
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

6.  Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.

Authors:  P J Russell; J Plomley; I H Shon; H O'Grady; N Pearce
Journal:  Cell Biophys       Date:  1993 Jan-Jun

7.  The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?

Authors:  B Altay; C Girgin; A Kefi; N Cikili
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.266

8.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.

Authors:  G A Choudry; P A Stewart; J A Double; M R Krul; B Naylor; G M Flannigan; T K Shah; J E Brown; R M Phillips
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

9.  The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group.

Authors:  L A Kiemeney; J A Witjes; A L Verbeek; R P Heijbroek; F M Debruyne
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.